Skip to Main Content

Paper Details

Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
Int J Cancer
24
2018
Author NameAffiliation
Eric PaquetInstitute of Bioengineering, Ecole Polytechnique Federale de Lausanne
Ingrid HedenfalkLund University, Skane University Hospital
Ingrid HedenfalkCREATE Health Strategic Center for Translational Cancer Research, Lund University
  • 1 - 3

Datasets

Release 1.2